IMRA News and Press, IMARA Inc. From 07/14/21

Gainers: AcelRx Pharmaceuticals ACRX +19%, GBS (GBS) +13%, Navidea Biopharmaceuticals (NAVB) +7%, Cellect Biotechnology (APOP) +6%, Adagene (ADAG) +2%.Losers: Allied Healthcare Products (AHPI) -34%, Allena Pharmaceuticals (ALNA) -31%, SCWorx (WORX)...

Allied Healthcare Products (AHPI) -24%.Glaukos (GKOS) -21% comments on the centers for medicare and medicaid services 2022 proposed physician fee scheduleAllena Pharmaceuticals (ALNA) -20% after launches $28M direct offeringIMARA (IMRA) -15% after secures $50M capital...

Imara (IMRA) has priced its public offering of common shares at $6.00/share, for gross proceeds of $50M.Underwriters' over-allotment is an additional $7.5M of shares.Closing date is July 16.Morgan Stanley, SVB Leerink and Cantor are acting as joint book-running managers for the offering....

BOSTON, July 13, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (the “Company”) (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, annou...

Imara (IMRA) announces that it has commenced a proposed underwritten public offering of $50M of shares.Intends to grant the underwriters a 30-day option to purchase up to an additional $7.5M of shares.Shares down 11% post market. For further details see: Imara shares slide on $50M ...

BOSTON, July 13, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (the “Company”) (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today...

BOSTON, June 30, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced the election of Lau...

The following slide deck was published by IMARA Inc. in conjunction with this event. For further details see: IMARA (IMRA) EHA Investor Presentations - Slideshow

BOSTON, June 17, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced the grant recipient...

Final data from 93-patient Phase 2a clinical trial show lower annualized rate of vaso-occlusive crises (VOCs) and longer time to first VOC on IMR-687 Interim open-label extension clinical trial data through eight months show increased HbF response and continuation of lower VOC r...